Patents by Inventor François-Xavier Mahon
François-Xavier Mahon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170007605Abstract: The present invention provides a method of treating Philadelphia positive (Ph+) leukemia, such as Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia (CML), in a human patient population comprising the steps of (a) administering a predetermined fixed therapeutically effective amount of an Bcr-Abl tyrosine kinase inhibitor, such as Imatinib, or a pharmaceutically acceptable salt thereof to human patients suffering from a Ph+ leukemia, (b) collecting at least one blood sample from said patients, (c) determining the plasma trough level (Cmin) of the Bcr-Abl tyrosine kinase inhibitor or of a metabolite thereof as well as the MMR rates, (d) assessing a discrimination potential of trough plasma concentrations for MMR and identifying a Cmin threshold for optimal sensitivity and specificity and (e) adjusting the dose of the inhibitor of the Bcr-Abl tyrosine kinase or a pharmaceutically acceptable salt thereof applied to the individual patients from said patient populatType: ApplicationFiled: September 22, 2016Publication date: January 12, 2017Applicant: Novartis AGInventors: Insa Gathmann, Francois-Xavier Mahon, Mathieu Molimard, Stephane Picard, Yanfeng Wang
-
Publication number: 20110190220Abstract: The present invention pertains to the use of defensin ?1 and/or defensin ?4, as a marker for predicting and following the response of a patient suffering from chronic myeloid leukaemia to a treatment with imatinib.Type: ApplicationFiled: July 17, 2009Publication date: August 4, 2011Inventors: Béatrice Turcq, Gabriel Etienne, Maryse Dupouy, François-Xavier Mahon, Bertrand Garbay, Patricia Costaglioli
-
Publication number: 20110129852Abstract: The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.Type: ApplicationFiled: July 12, 2010Publication date: June 2, 2011Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Jay Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Müller, Oliver Gerhard Ottmann, Markus Warmuth
-
Publication number: 20100021920Abstract: The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production ofType: ApplicationFiled: August 21, 2009Publication date: January 28, 2010Inventors: Christophe Barthe, Susan Branford, Amie Corbin, Brian Jay Druker, Justus Duyster, Andreas Hochhaus, Timothy Hughes, Sebastian Kreil, Thlbaut Leguay, Francois-Xavier Mahon, Gèrald Marit, Martin Müller, Christian Peschel, Claude Preudhomme, Catherine Roche Lestienne, Zbigniew Rudzki
-
Publication number: 20100021921Abstract: The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production ofType: ApplicationFiled: August 21, 2009Publication date: January 28, 2010Inventors: Christophe Barthe, Susan Branford, Amie Corbin, Brian Jay Druker, Justus Duyster, Andreas Hochhaus, Timothy Hughes, Sebastian Kreil, Thibaut Leguay, Francois-Xavier Mahon, Gerald Marit, Martin Muller, Christian Peschel, Claude Preudhomme, Catherine Roche Lestienne, Zbigniew Rudzki
-
Publication number: 20090281113Abstract: The present invention provides a method of treating Philadelphia positive (Ph+) leukemia, such as Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia (CML), in a human patient population comprising the steps of (a) administering a predetermined fixed amount of a Bcr-Abl tyrosine kinase inhibitor, such as Imatinib, or a pharmaceutically acceptable salt thereof to human patients suffering from a Ph+ leukemia, (b) collecting at least one blood sample from said patients, (c) determining the plasma trough level (Cmin) of the Bcr-Abl tyrosine kinase inhibitor or of a metabolite thereof as well as the MMR rates, (d) assessing a discrimination potential of trough plasma concentrations for MMR and identifying a Cmin threshold for optimal sensitivity and specificity and (e) adjusting the dose of the inhibitor of the Bcr-Abl tyrosine kinase or a pharmaceutically acceptable salt thereof applied to the individual patients from said patient population and, optionally, futureType: ApplicationFiled: September 20, 2007Publication date: November 12, 2009Applicant: NOVARTIS AGInventors: Insa Gathmann, Francois-Xavier Mahon, Mathieu Molimard, Stephane Picard, Yanfeng Wang
-
Publication number: 20090191606Abstract: The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1 -ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.Type: ApplicationFiled: December 17, 2008Publication date: July 30, 2009Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Jay Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Muller, Oliver Gerhard Ottmann, Markus Warmuth
-
Publication number: 20060148058Abstract: The tides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit they tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.Type: ApplicationFiled: January 31, 2006Publication date: July 6, 2006Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Muller, Oliver Ottmann, Markus Warmuth
-
Patent number: 6987103Abstract: The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising: (a) selecting or identifying an animal suffering from chronic myelogenous leukemia or a related myeloproliferative disorder and showing resistance or intolerance to treatment with STI571; and (b) administering to the animal homoharringtonine. In a preferred embodiment, the animal is a human being.Type: GrantFiled: March 27, 2003Date of Patent: January 17, 2006Assignee: Stragen Pharma S.A.Inventors: Jean-Pierre Robin, François-Xavier Mahon, Hervé Maisonneuve, Frederick Maloisel, Julie Blanchard
-
Publication number: 20050202519Abstract: The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production ofType: ApplicationFiled: October 4, 2002Publication date: September 15, 2005Inventors: Christophe Barthe, Susan Branford, Amie Corbin, Brian Druker, Justus Duyster, Andreas Hochhaus, Timothy Hughes, Sebastian Kreil, Thibaut Leguay, Francois-Xavier Mahon, Gerald Marit, Martin Muller, Chriatian Peschel, Claude Preudhomme, Catherine Roche Lestienne, Zbigniew Rudzki
-
Publication number: 20050049268Abstract: The invention relates to a method of treating a warm-blooded animal, especially a human, having depigmented hair or subject to hair depigmentation comprising administering to the animal a useful amount of a) at least one Abl, Kit and/or platelet-derived growth factor (PDGF) receptor tyrosine kinases inhibitor, the use of a) and at least one cosmetic acceptable carrier, to retard, prevent, suppress, and/or revere the depigmentation of hair, the use of a) for the preparation of a medicament for the treatment of a disease characterized by hair depigmentation and a topical cosmetic composition comprising a useful amount of at least one Abl, Kit or PDGF receptor tyrosine kinases inhibitor.Type: ApplicationFiled: November 20, 2002Publication date: March 3, 2005Inventors: Francois-Xavier Mahon, Pascale Cony-Makhoul, Gabriel Etienne
-
Publication number: 20040019036Abstract: The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising:Type: ApplicationFiled: March 27, 2003Publication date: January 29, 2004Inventors: Jean-Pierre Robin, Francois-Xavier Mahon, Herve Maisonneuve, Frederick Maloisel, Julie Blanchard
-
Publication number: 20030170851Abstract: The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.Type: ApplicationFiled: October 3, 2002Publication date: September 11, 2003Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Jay Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Muller, Oliver Gerhard Ottmann, Markus Warmuth